Esperion Therapeutics, Inc.

NASDAQ:ESPR

Biotechnology

Healthcare
$3.18 -0.32%

+$0.00 today

Market cap
$661.15M
Beta
1.07
P/E (TTM)
-107.3
EPS (TTM)
-$0.03
52W Low $0.95High $4.18

Volume 0.00M

Average 12.29M

ESPR Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Esperion Therapeutics, Inc.NASDAQ: ESPR

Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026

Other income / expenses remains negative

Q1 FY2026 other income / expenses was -$18.62M, compared with -$18.36M a year earlier. Trailing-twelve-month other income / expenses was -$81.37M.

Context

  • Other income / expenses amounted to 20.1% of revenue in FY2025, down 11.8 pp from a year earlier.
  • Other income / expenses grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly other income / expenses holds near -$18.62M or moves back toward the trailing-twelve-month quarterly average of -$20.34M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$18.62M+13.7% QoQ
Last fiscal yearDec 2025
-$81.11M+23.6% YoY
LTMMar 2026
-$81.37M+28.2% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-1.4%——
1 year+23.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
(81.11M) USD
Year-over-year change
+23.6%

Other Income / Expenses vs competitors

How ESPR compares with its peers on the latest reported figures

  • Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +28.2% is the 4th highest of 10, against a peer median of +7.9%.
  • Other income / expenses amounts to 19.5% of revenue for ESPR, versus a peer median of 10.0%.
ESPR Competitors
Other Income / Expenses for ESPR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$16.66M USD+19.9%+94.7%—
ABSIAbsci CorporationLTM Mar 2026$10.19M USD+78.9%+90.7%555.0%
SIGASIGA Technologies, Inc.LTM Mar 2026$6.29M USD+7.9%+67.2%6.7%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$3.76M USD+136.9%——
SNDLSNDL Inc.LTM Mar 2026-CA$5.06M CAD-0.5%—0.5%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026-$13.02M USD+0.4%—25.9%
OFIXOrthofix Medical Inc.LTM Mar 2026-$26.23M USD+28.5%—3.2%
RGNXREGENXBIO Inc.LTM Mar 2026-$33.33M USD-9907.5%—37.9%
EBSEmergent BioSolutions Inc.LTM Mar 2026-$67.7M USD-280.1%—10.0%
ESPREsperion Therapeutics, Inc.LTM Mar 2026-$81.37M USD+28.2%—19.5%
Peer median (excluding ESPR) —+7.9%+90.7%10.0%

Competitors are the stored peer set for ESPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue78.45M75.48M116.33M332.31M403.14M
Cost of Revenue14.22M26.97M43.27M68.6M129.22M
Gross Profit64.23M48.51M73.07M263.71M273.91M
Gross Margin81.9%64.3%62.8%79.4%67.9%
Research & Development105.98M118.93M86.11M46.24M47.85M
Selling, General & Admin184.99M109.08M142.52M163.07M165.79M
Operating Expenses290.96M228.01M228.63M209.31M213.64M
Depreciation & Amortization612K500K164K63K105K
EBITDA(222.14M)(176.35M)(150.11M)7.57M63.87M
EBITDA Margin-283.2%-233.7%-129.0%2.3%15.8%
Operating Income(226.73M)(179.5M)(155.56M)54.4M60.27M
Operating Margin-289.0%-237.8%-133.7%16.4%15.0%
Interest Income00003.5M
Interest Expense46.35M56.81M58.98M59.25M84.6M
Other Income / Expenses(42.38M)(54.16M)(53.69M)(106.15M)(81.11M)
Income Before Tax(269.11M)(233.66M)(209.25M)(51.75M)(20.84M)
Pre-Tax Margin-343.0%-309.6%-179.9%-15.6%-5.2%
Income Tax Expense00001.84M
Net Income(269.11M)(233.66M)(209.25M)(51.75M)(22.68M)
Net Margin-343.0%-309.6%-179.9%-15.6%-5.6%
EPS (Basic)(11.03)(4.33)(2.03)(0.28)(0.11)
EPS (Diluted)(11.03)(4.33)(2.03)(0.28)(0.11)
Weighted Avg Shares28.9M66.41M103.11M187.18M207.87M
Weighted Avg Shares (Diluted)28.9M66.41M103.11M187.18M207.87M

Esperion Therapeutics, Inc.

NASDAQ:ESPR

Intrinsic Alpha fair value

Locked

Current Price

$3.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.